Alkermes ALKS
-
Alkermes ( ALKS ): FQ4 EPS of -$0.14 beats by $0.02. Revenue of $103M (+155% Y/Y) beats by $5M. (PR)
Alkermes ( ALKS ): FQ4 EPS of -$0.14 beats by $0.02 . Revenue of $103M (+155% Y/Y) beats by $5M . ( PR ) Post your comment!
-
Alkermes , Inc. ALKS Q4 2012 Earnings Call Transcript
… thank you for standing by. Welcome to the Alkermes Conference Call to discuss the Company's ..... advised that this call is being recorded at Alkermes ' request. Thanks. Welcome to Alkermes PLC conference call to discuss our financial …
-
Cramer's Mad Money - The Hospitality Index Revisited (5/10/12)
By SA Editor Miriam Metzinger : Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday May 10. Hospitality Index: Whole Foods ( WFM ), Chipotle Mexican Grill ( CMG ), Goldman Sachs ( GS ), Apple ( AAPL ), Dreamworks ( DWA ), Southwest Airlines ( LUV ), Amazon ( AMZN
-
Elan's Tysabri Performance as Expected in 1Q, but We're Bearish on Upcoming Bapi Data
… to $1.7 billion). Elan's balance sheet continues to improve, and the sale of three fourths of the firm's Alkermes ALKS shares has added $381 million in cash to its books. Not including the firm's investments, Elan has actually established …
-
Top Mid-Cap Biotech Stocks Being Accumulated By Legendary Fund Managers
By Ganaxi Small Cap Movers : The biotech group as represented by the NYSE ARCA Biotech Index ($BTK) has been strong this year, now up over 31% YTD. With both the market and the biotech sector in strong bull mode, now maybe an opportune time to go 'shop' for biotech stocks. In this article, via an
-
Mid Cap Biotech Stocks Being Accumulated By The World's Largest Money Managers
By Ganaxi Small Cap Movers : The biotech group is among the largest in the market in terms of the number of companies, which number well over 300. Within the group, large-caps (those with market-caps over $5 billion) have well established commercialized product portfolios that generate revenues, ...
-
Long Undervalued, Is Alkermes Still A Bargain?
… Stephen Simpson : For a large part of its history, Alkermes ( ALKS ) never quite seemed to get its due from the Street ..... On A Multi-Lane Highway With the EDT merger done, Alkermes collects royalties from a veritable who's who of Big …
-
The Rumor Behind Amylin's Spike Makes Sense
By Stephen Simpson : Amylin Pharmaceuticals ( AMLN ) has always been a feast-or-famine sort of stock, as the company has long experience in surmounting the difficulties of dealing with the FDA (Symlin and Bydureon, most notably), competition, and its own now-former partner Lilly ( LLY ). Although
-
Premarket gainers: [[MWA]] +18%. [[XOMA]] +8%. [[SQNM]] +7%. [[NBG]] +5%. [[GNOM]] +4%. [[CCI]] +4%. [[RAD]] +5%. [[MWW]] +4%. [[DB]] +4%. [[ING]] +4%. [[RIO]] +3%. [[MT]] +3%. [[BUD]] +3%. [[DRYS]] ...
… MT +3% . BUD +3% . DRYS +3% . ARMH +3% . STO +3% . UBS +3% . SINA +3% . AEO +3% . Losers: DNDN -13% . STP -6% . ALKS -5% . WSM -4% . AMLN -4% . MCD -3% . CIGX -3% . UAL -3% . AGNC -3% . Post your comment!
-
Bydureon Physician Survey: Results Yield Insight Into Launch Trajectory
… for Amylin Pharmaceuticals (NASDAQGS: AMLN ) and Alkermes ' (NASDAQGS: ALKS ) diabetes drug Bydureon . The companies began marketing ..... approval was not straightforward for Amylin and Alkermes , and Amylin's marketing partner for the drug …